J Rodrigo Mora
Chief Scientific Officer Breeze Bio
Physician-scientist and R&D executive with more than a decade leading discovery and translational organizations across large pharma and venture-backed biotech, built on a Harvard Medical School faculty career in immunology. Currently CSO at BreezeBio, setting strategy for a tolerogenic nanoparticle platform in autoimmune disease. Prior VP and platform immunology head at Moderna, therapeutic-area and clinical lead at Takeda, and disease-biology lead at Janssen. Deep expertise in immune tolerance and nanoparticle-based mRNA delivery with over 50 articles published in leading journals and over 14,000 citations. Extensive experience conceptualizing and implementing scientific research strategies and leading scientific teams, with a track record spanning target identification through IND and Phase 1/2 clinical leadership.
Seminars
- Examining why antigen-specific immune tolerance may need complementary therapies to succeed, to identify where monotherapy alone falls short, and set out where combination approaches could close that gap
- Reviewing which therapies can safely be combined with tolerance induction to distinguish combinations that support the tolerogenic effect from those that interfere with it and build a clearer picture of viable pairing options
- Exploring how depletion-based therapies and tolerance induction could work together, to consider how sequencing or timing might allow one to reinforce the other, and outline a possible framework for combination strategy design
- Introduction to the NanoGalaxy hydrophilic nanoparticle (HNP) mRNA delivery platform
- HNP-mRNA biodistribution, immune cell engagement, and safety in mice and nonhuman primates
- Application of the HNP-mRNA platform to induce immune tolerance in autoimmune indications
